ProCE Banner Activity

Have We Reached the Tipping Point for Broad Molecular Profiling in Advanced NSCLC?

Clinical Thought
Next-generation sequencing can identify both new and well-established markers in NSCLC. In this commentary, H. Jack West, MD, discusses his thoughts on broad genomic testing in today’s care of patients with advanced NSCLC.

Released: August 09, 2017

Expiration: August 08, 2018

No longer available for credit.

Share

Faculty

Heather J. Jackson

Heather J. Jackson, PhD, FNP-BC, NEA-BC, FAANP

Associate Professor
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University School of Nursing
Administrative Director of Advanced Practice
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

Celgene

Genentech Roche Virology

Lilly

Merck Oncology

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Heather J. Jackson, PhD, FNP-BC, NEA-BC, FAANP

Associate Professor
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University School of Nursing
Administrative Director of Advanced Practice
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

H. Jack West, MD, has disclosed that he has received consulting fees from Ariad, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genentech/Roche, Merck, and Pfizer and fees for non-CME/CE services from Ariad, Genentech/Roche, and Lilly.